ArticleNeuroradiology2026
MRI Differentiation of Anaplastic Ependymoma and Medulloblastoma with Fourth Ventricular Outlet Extension in Children.
Article in Neuroradiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMedulloblastoma and anaplastic ependymoma (AE) are common malignant pediatric posterior fossa tumors with differing outcomes. While tumor extension through the fourth ventricular outlets (TETFVO) is common in AEs, it also occurs in some medulloblastomas, which complicates diagnosis. This study aimed to improve pretreatment differentiation between medulloblastomas with TETFVO and AEs for better treatment planning and outcome prediction.
methodsFrom 2005 to 2024, we retrospectively analyzed 21 pediatric AE patients and 36 patients with medulloblastoma with TETFVO, assessing clinical data and MRI features, including lesion signals, intratumoral morphologies, and peritumoral/distal involvement.
resultsCompared with medulloblastomas with TETFVO, AE patients had a significantly higher tumor recurrence/progression rate (p < 0.001) and shorter survival (p = 0.036). On MRI, AEs were larger (p = 0.007); had a higher apparent diffusion coefficient value (ADCmin) (p < 0.001), higher ADC ratio (p < 0.001), lower diffusion-weighted imaging ratio (p < 0.001), and greater caudal tumor extension (14.36 ± 8.74 mm vs. 7.90 ± 4.10 mm, p = 0.016) with a higher length/width ratio; and were more prone to encase the brainstem (p < 0.001) and vascular structures (p < 0.001). AEs had more lobulated/ring-like enhancement patterns (14/21 [82.4%]), whereas medulloblastomas appeared more patchy/diffused (27/36 [81.8%]) (p < 0.001). The tumor central vein sign was nearly exclusive to medulloblastomas (p = 0.002).
conclusionCompared with AEs, medulloblastomas with TETFVO show lower ADCmin, less brainstem or vascular encasement, less caudal extensions, and the tumor central vein sign. These distinct features can aid in treatment planning and outcome prediction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.